How long does it take for Eltrombopag/Eltrombopag to be effective?

Eltrombopag/Eltrombopag (Eltrombopag) is an oral, small-molecule, non-peptide thrombopoietin receptor agonist that can promote platelet production and is mainly used to increase the rate of certain chronic immune thrombocytopenia (ITP), chronic hepatitis C virus (HCV) patients, low platelet count in patients with severe aplastic anemia (ITP). Typically, eltrombopag begins to take effect 1 to 2 weeks after oral administration, and platelet levels will gradually increase. However, specific effects may vary from person to person, depending on factors such as the patient's physical condition, severity of illness, and response to medications.

In trials of adult patients with chronic immune thrombocytopenia, an increase in platelet counts was detectable 1 week after starting treatment with eltrombopag; maximal response was seen after 2 weeks of treatment. Of the 26 pediatric patients who responded to eltrombopag treatment during 6 of the 8 weeks (weeks 5 to 12) of the Petit2 trial (≥50x10^9/L, no rescue), 62% had an initial response observed in the first 2 weeks of treatment. The primary purpose of eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C is to initiate and maintain interferon therapy. Two weeks is the median time for patients enrolled in the clinical trial to reach the target platelet count≥90x10^9/L, and a total of 95% of the patients were able to receive antiviral treatment after receiving eltrombopag.

It is unclear how quickly the combination of eltrombopag and immunosuppressive therapy works in patients with severe aplastic anemia who have previously been untreated (first-line therapy). However, 87% of patients who received eltrombopag once daily during the first 6 months of their treatment plan had a complete or partial response to eltrombopag and combined immunosuppressive therapy by 3 months. A total of 24 of the 25 pediatric patients also had a complete or partial response at 6 months, a key outcome measured in the trial. The exact rate of response in patients with severe aplastic anemia who had not responded to previous immunosuppressive therapy was also unknown, with 44% of patients having at least some hematologic response to treatment at 12 weeks, and 9 of 11 patients no longer requiring platelet transfusions at that time.

However, it is important to note that while eltrombopag is effective in raising platelet counts in most cases, not all patients will respond to the drug. Additionally, even if a patient begins to respond to the medication, it may take some time to see noticeable results. Therefore, when using eltrombopag, doctors need to carefully evaluate its efficacy and safety based on the patient's specific situation, and make adjustments as necessary.

Overall, eltrombopag/Eltrombopag is an effective drug that can help patients increase their platelet counts. Although the specific onset of effect may vary from person to person, usually, patients will see obvious effects after 1 to 2 weeks of oral administration. However, to ensure the safety and effectiveness of the drug, patients should follow their doctor's advice and guidance when using eltrombopag.